Randomized phase II clinical trial of adriamycin, methotrexate, and actinomycin‐d in advanced measurable pancreatic carcinoma. A gastrointestinal tumor study group report

Philip S. Schein, Philip T. Lavin, Charles G. Moertel, Stephen Frytak, Richard G. Hahn, Michael J. O'Connell, Richard J. Reitemeier, Joseph Rubin, Allen J. Schutt, Louis H. Weiland, M. Kalser, J. Barkin, H. Lessner, R. Mann‐Kaplan, D. Redlhammer, M. Silverman, M. Troner, H. O. Douglass, S. Milliron, J. LokichJ. Brooks, J. Chaffe, A. Like, N. Zamcheck, K. Ramming, J. Bateman, H. Spiro, E. Livstone, A. Knowlton

Research output: Contribution to journalArticle

58 Scopus citations

Abstract

Sixty-six patients with advanced pancreatic carcinoma were randomized to receive single agent chemotherapy with either adriamycin, methotrexate, or actinomycin-D using conventional dose, route and schedule of administration. All patients had measurable lesions which were used for objective assessment of response. For adriamycin, 2 of 25 patients (8%) evidenced a partial response (2 of 15 (13%) previously untreated patients). One of 25 patients treated with methotrexate and one of 28 who received actinomycin-D responded. The duration of responses ranged from 43-64 days for those patients with no chemotherapy prior to study entry. The median survival of patients who received adriamycin as initial treatment was 12 weeks compared to 8 weeks for methotrexate and 6 weeks for actinomycin-D therapy.

Original languageEnglish (US)
Pages (from-to)19-22
Number of pages4
JournalCancer
Volume42
Issue number1
DOIs
StatePublished - Jul 1978

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Randomized phase II clinical trial of adriamycin, methotrexate, and actinomycin‐d in advanced measurable pancreatic carcinoma. A gastrointestinal tumor study group report'. Together they form a unique fingerprint.

  • Cite this

    Schein, P. S., Lavin, P. T., Moertel, C. G., Frytak, S., Hahn, R. G., O'Connell, M. J., Reitemeier, R. J., Rubin, J., Schutt, A. J., Weiland, L. H., Kalser, M., Barkin, J., Lessner, H., Mann‐Kaplan, R., Redlhammer, D., Silverman, M., Troner, M., Douglass, H. O., Milliron, S., ... Knowlton, A. (1978). Randomized phase II clinical trial of adriamycin, methotrexate, and actinomycin‐d in advanced measurable pancreatic carcinoma. A gastrointestinal tumor study group report. Cancer, 42(1), 19-22. https://doi.org/10.1002/1097-0142(197807)42:1<19::AID-CNCR2820420103>3.0.CO;2-4